PFE
PFIZER INC
NYSE · Healthcare · Drug Manufacturers - General · US
$27.60
−0.14%Year over year
Reported trailing growth
- Revenue
- -0.2%
- EBITDA
- -44.6%
- EBIT
- -15.4%
- EPS
- -60.1%
- Free cash flow
- -11.7%
- Operating cash flow
- -11.8%
Forward estimates
Based on analyst estimates
- Revenue
- -4.6%
- EBITDA
- +115.5%
- EPS
- +265.9%
Three-year CAGR
- Revenue
- -14.6%
- EBITDA
- -28.3%
- EBIT
- -25.6%
- Net income
- -37.2%
- EPS
- -37.6%
- Free cash flow
- -29.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026